The Prostate Imaging – Reporting and Data System Version 2 (PI-RADS™ v2) is a standardized protocol for multiparametric magnetic resonance imaging (mpMRI) of the prostate, developed by an international collaboration including the American College of Radiology (ACR), European Society of Uroradiology (ESUR), and AdMeTech Foundation. It aims to promote global standardization in the acquisition, interpretation, and reporting of mpMRI examinations, enhancing detection and characterization of clinically significant prostate cancer. PI-RADS™ v2 establishes minimum technical parameters, standardizes terminology, and provides assessment categories to assist in biopsy selection and management. The system is designed for routine clinical practice and research data collection. Key features include: - **Technical Specifications**: Emphasizes the inclusion of T2W, DWI, and DCE sequences, with specific recommendations for magnetic field strength, endorectal coils, and computer-aided evaluation (CAE) technology. - **Benign Findings**: Describes common benign conditions such as benign prostatic hyperplasia (BPH), hemorrhage, cysts, calcifications, prostatitis, atrophy, and fibrosis. - **Assessment and Reporting**: Uses a 5-point scale to assess the likelihood of clinically significant cancer based on mpMRI findings. It provides guidelines for lesion measurement and reporting, emphasizing the importance of correlation with pathology. - **Multiparametric MRI (mpMRI)**: Details the acquisition and interpretation of T1W, T2W, DWI, and DCE sequences, including technical specifications and caveats. - **Staging**: Discusses the use of mpMRI for determining the T stage and assessing extraprostatic extension (EPE) and lymph node involvement. The document also includes contributions from various experts and working groups, highlighting the collaborative nature of the development process.The Prostate Imaging – Reporting and Data System Version 2 (PI-RADS™ v2) is a standardized protocol for multiparametric magnetic resonance imaging (mpMRI) of the prostate, developed by an international collaboration including the American College of Radiology (ACR), European Society of Uroradiology (ESUR), and AdMeTech Foundation. It aims to promote global standardization in the acquisition, interpretation, and reporting of mpMRI examinations, enhancing detection and characterization of clinically significant prostate cancer. PI-RADS™ v2 establishes minimum technical parameters, standardizes terminology, and provides assessment categories to assist in biopsy selection and management. The system is designed for routine clinical practice and research data collection. Key features include: - **Technical Specifications**: Emphasizes the inclusion of T2W, DWI, and DCE sequences, with specific recommendations for magnetic field strength, endorectal coils, and computer-aided evaluation (CAE) technology. - **Benign Findings**: Describes common benign conditions such as benign prostatic hyperplasia (BPH), hemorrhage, cysts, calcifications, prostatitis, atrophy, and fibrosis. - **Assessment and Reporting**: Uses a 5-point scale to assess the likelihood of clinically significant cancer based on mpMRI findings. It provides guidelines for lesion measurement and reporting, emphasizing the importance of correlation with pathology. - **Multiparametric MRI (mpMRI)**: Details the acquisition and interpretation of T1W, T2W, DWI, and DCE sequences, including technical specifications and caveats. - **Staging**: Discusses the use of mpMRI for determining the T stage and assessing extraprostatic extension (EPE) and lymph node involvement. The document also includes contributions from various experts and working groups, highlighting the collaborative nature of the development process.